Amgen And Abgenix Complete Biologics License Application For FDA Approval Of Panitumumab

THOUSAND OAKS, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--March 30, 2006--Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for panitumumab. The potential indication is for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy, including oxaliplatin and/or irinotecan containing regimens. The rolling BLA submission was initiated in December 2005.

MORE ON THIS TOPIC